{"entity":{"id":"ken-herrmann","kind":"person","name":"Ken Herrmann","aka":[],"tldr":"Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes.","summary":"Ken Herrmann was a lead investigator of VISION and of the German multicentre 177Lu-PSMA-617 registry, and leads the Essen theranostics centre that has treated thousands of patients with PSMA and somatostatin receptor radioligands. He has chaired the EANM oncology committee, co-authored the Lancet Oncology series on theranostics, and leads trials of alpha emitters and new targets such as FAP.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herrmann%20K%5BAuthor%5D%20theranostics%20PSMA"}],"tags":["radioligand","nuclear-medicine","germany"],"related":[],"cancers":["prostate","neuroendocrine"],"sections":[],"technologies":["radioligand-therapy","psma-pet","fapi-pet"],"targets":["psma","fap"],"drugs":["pluvicto","lutathera"],"companies":[],"institutions":["essen-wtz","eanm"],"pathways":[],"terms":[],"trials":["vision"],"people":[],"bottlenecks":[],"keyPapers":["paper-vision-nejm-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Nuclear Medicine, University Hospital Essen","institutionId":"essen-wtz","specialisms":["Theranostics","PSMA radioligand therapy","Nuclear medicine","Radiopharmaceutical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herrmann%20K%5BAuthor%5D%20theranostics%20PSMA"}],"papers":[{"title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer (VISION)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2107322"},{"title":"Radiotheranostics: a roadmap for future development","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(19)30821-6"}],"orcid":"0000-0002-9662-7259"},"route":"/people/ken-herrmann/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"fapi-pet","kind":"technology","name":"FAPI PET","route":"/technologies/fapi-pet/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/"},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"drug":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"institution":[{"id":"eanm","kind":"institution","name":"European Association of Nuclear Medicine","route":"/institutions/eanm/"},{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/"}],"trial":[{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/"}],"paper":[{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/"}]}}